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Although the prevalence of chronic hepatitis B has de-
creased considerably in recent years due to widespread 
use of the hepatitis B virus (HBV) vaccine, its prevalence 
still remains high in adults, and this can place a signiﬁ  cant 
burden on health care in areas with endemic HBV. Since 
the introduction of nucleos(t)ide analogues (NUCs), there 
has been marked improvement in the care of patients with 
chronic hepatitis B, resulting in increased survival. However, 
the emergence of drug resistance in patients treated with 
NUCs is a major concern. The number of multi-drug resistant 
patients is increasing, and many patients may not respond to 
the currently available drugs. In this review, we describe the 
current status of NUC therapy for antiviral-naïve and -resis-
tant patients. (Gut Liver 2011;5:278-287)
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is an important 
health problem affecting approximately 400 million people 
worldwide. Chronic HBV infection can progress to cirrhosis, 
decompensated cirrhosis, hepatocellular carcinoma (HCC), and 
death. The prevalence of HBV infection has decreased dramati-
cally following widespread use of HBV vaccine in Korea, an 
endemic area. However, chronic HBV infection is still prevalent 
in the population in their 20s in Korea,
1 and has remained a sig-
nificant burden to the health care system. The circulating level 
of HBV DNA has been proved as the most important correlating 
factor in the development of cirrhosis and HCC. The suppression 
of HBV replication can reduce necroinflammatory activity and 
prevent progression to cirrhosis and HCC. Several nucleos(t)ide 
analogues (NUCs) have been developed over the past decade, 
and the administration of NUCs has played a crucial role in the 
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treatment of chronic HBV infection. Despite their potent anti-
HBV effects, NUCs cannot eradicate HBV infection, and for this 
reason, long-term therapy is necessary. The major drawback of 
long-term monotherapy with NUCs is the emergence of drug 
resistance. The emergence of resistance limits the efficacy of the 
antiviral drugs, raising a serious concern in clinical practice. The 
prevention of drug resistance and selection of appropriate treat-
ment options in the face of drug resistance are important for 
reducing morbidity and mortality of patients with chronic HBV 
infection.
GOALS OF TREATMENT
The goal of therapy is to improve survival by preventing pro-
gression of chronic hepatitis to cirrhosis, end-stage liver disease 
or HCC. Short-term goals include reduction in HBV DNA levels, 
persistent alanine aminotransferase (ALT) normalization, and 
hepatitis B e antigen (HBeAg) seroconversion. Loss of hepatitis 
B surface antigen (HBsAg) is an ideal end point, but this rarely 
occurs. NUCs can not completely eradicate HBV infection as 
they show little effectiveness in eliminating covalently closed 
circular DNA in the nucleus of infected hepatocytes. Long-term 
administration on NUCs is required in order to effectively treat 
patients with chronic HBV infection. 
The European Association for the Study of the Liver (EASL) 
guidelines suggest that therapy must reduce HBV DNA to as low 
a level as possible, ideally below the lower limit of detection by 
the real-time PCR assay.
2 Persistent viremia has been associated 
with frequent development of antiviral resistance. 
DEFINITION OF FAILED RESPONSE AND VIRAL RESIS-
TANCE
1. Primary non-response
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decrease in HBV DNA level from baseline after 3 months of 
therapy based on the EASL guidelines.
2 The American Associa-
tion for the Study of Liver Disease (AASLD) guidelines define 
primary non-response as failure to achieve a 2 log10IU/mL de-
crease in HBV DNA after at least 6 months of therapy (Table 1).
3 
It may be due to poor compliance or low antiviral activity. A 
switch to a more potent drug is recommended for patients with 
primary non-response. 
2. Partial response
The EASL guidelines propose that partial virologic response 
is defined as a decrease in HBV DNA of more than 1 log10IU/
mL but detectable HBV DNA by real time PCR at week 24 or 48, 
depending on the genetic barrier of anti-viral drugs (Table 1).
2 
If drugs with a high genetic barrier such as entecavir (ETV) or 
tenofovir (TDF) are being administered, antiviral response can 
be assessed at week 48. Adefovir (ADV) has delayed antiviral 
effect. Thus, these patients can also be assessed at week 48. A 
partial virologic response to antiviral drugs correlates with the 
risk of promoting antiviral resistance. The serum HBV DNA 
level at week 24 of therapy was found to be associated with 
the emergence of antiviral resistance in patients treated with 
telbivudine (LdT) or lamivudine (LAM).
4 Patients with HBV 
DNA level >1,000 copies/mL at week 24 of therapy correlated 
with high rates of resistance when compared to those with a 
low HBV DNA level. A prospective cohort study of untreated 
hepatitis B patients showed that the risk for cirrhosis and HCC 
was higher in patients with HBV DNA levels >10,000 copies/mL 
than those with HBV DNA <10,000 copies/mL.
5,6 International 
practice guidelines recommend treating chronic hepatitis B pa-
tients with HBV DNA levels >10,000 copies/mL using antiviral 
drugs. When partial virologic response is identified, antiviral 
treatment should be modified. 
3. Virologic breakthrough
Virologic breakthrough is defined as an increase in serum 
HBV DNA by >1 log10copies/mL above nadir after achieving a 
virologic response during treatment (Table 1).
2,3 Drug-noncom-
pliance is frequently associated with virologic breakthrough. 
Therefore compliance should be confirmed at the time of vi-
rologic breakthrough. If virologic breakthrough occurs, serum 
HBV DNA increases progressively despite continuous treatment 
followed by an elevation in ALT level. A test for genotypic resis-
tance is needed to confirm the diagnosis and select appropriate 
treatment options. For patients presenting with mild elevation 
in HBV DNA and normal ALT, additional tests for HBV DNA are 
also necessary.
NUCLEOS(T)IDE ANALOGUES
A number of NUCs have been developed and used for the 
treatment of patients with chronic HBV infection. NUCs inhibit 
viral polymerase activity, thus affecting negative strand and 
positive strand DNA synthesis.
7 LAM, an analogue of dideoxy-
cytidine, was the first approved HBV polymerase inhibitor. LAM 
is the prototype of the L-nucleoside family. The triphosphate 
form of LAM inhibits nascent viral DNA synthesis. Other NUCs 
belonging to the L-nucleoside family are emtricitabine, LdT, and 
clevudine. ADV and TDF belong to the acyclic D-nucleotide, 
while ETV to the cyclic D-nucleoside. ADV and TDF are phos-
phorylated forms of nucleotide analogues. Long-term adminis-
tration of drugs belonging to the L-nucleoside family is associ-
ated with the frequent development of antiviral resistance, when 
compared to drugs belonging to D-nucleos(t)ide analogues (Table 
2). 
Table 1. Definition of a Response to Antiviral Therapy for Chronic Hepatitis B
AASLD* EASL
̈ APASL
̉
Primary non-response Decrease in serum HBV DNA by <2 
log10IU/mL after at least 24 weeks of 
therapy
Decrease in serum HBV DNA less 
than 1 log10IU/mL from baseline at 3 
months of therapy
Reduction of serum HBV-DNA <1 log 
IU/mL at 12 weeks of oral antiviral 
therapy in a compliant patient
Partial virological 
response
Decrease in serum HBV DNA of more 
than 1 log10IU/mL but detectable 
HBV DNA by real-time PCR assay
§
Virological break-
through
Increase in serum HBV DNA by >1 
log10 (10-fold) above nadir after 
achieving virologic response, during 
continued treatment 
Increase in serum HBV DNA level of 
more than 1 log log10IU/mL com-
pared to nadir (lowest level) HBV 
DNA level on therapy
>1 log IU/mL increase in serum HBV-
DNA from nadir of initial response 
during therapy as confirmed 1 
month later
HBV, hepatitis B virus.
*American Association for the Study of Liver Disease guidelines, Hepatology 2009;50:661-662;
3 
̈European Association for the Study of the Liver 
guidelines, J Hepatol 2009;50:227-242;
2 
̉Asian-Pacific Association for Study of the Liver recommendations, Hepatol Int 2008;2:263-283; 
§Partial 
virologic response should be assessed at 24 weeks of treatment for lamivudine and telbivudine and 48 weeks of treatment for entecavir, adefovir 
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1. Lamivudine
Lamivudine (LAM), the (-) enantiomer of 3`-thiacytidine, is 
an oral 2’, 3’-dideoxynucleoside that inhibits DNA synthesis 
by terminating the nascent proviral DNA chain. Unlike other 
dideoxynucleosides, LAM does not inhibit mitochondrial DNA 
or bone marrow progenitor cells at concentrations that block 
the synthesis of HBV DNA, and it is not incorporated into mito-
chondrial DNA.
8 The recommended dose of LAM for adults with 
normal renal function (creatinine clearance >50 mL/min) and 
no HIV co-infection is 100 mg orally once daily. Dose reduction 
is necessary for patients with renal insufficiency (Table 3). 
In HBeAg-positive chronic hepatitis B patients, HBeAg se-
roconversion at 1 year was seen in 16-18% of patients who 
received LAM compared with 4-6% of untreated controls. Un-
detectable serum HBV DNA was noted in 44-60% of patients, 
and ALT normalization was observed in 41-72%. Histologic 
improvement defined as a reduction in the necroinflamma-
Table 2. Potency and Resistance of Currently Available Nucleos(t)ide 
Analogues
Antiviral 
potency
Genetic 
barrier
Resistant pattern
Pyrimidine analogues
  L-nucleosides
    Lamivudine Moderate Low rtM204V/I±rtL180M
    Emtricitaine Low Low rtM204V/I±rtL180M
    Telbivudine High Low rtM204I
    Clevudine High Low rtM204I
Purine analogues
  Cyclic D-nucleoside
    Entecavir High High rtM204V/I±rtL180M
plus rtT184, rtS202, rtM250
  Acyclic D-nucleotides
    Adefovir Low Moderate rtA181T/V, rtN236T
    Tenofovir High High rtA181T/V, rtN236T
Table 3. Adjustment of Adult Dosage of Nucleos(t)ide Analogues in Accordance with Creatinine Clearance
Creatinine clearance (mL/min) Recommended dose
Lamivudine
  ≥50 100 mg qd
  30-49 100 mg first dose, then 50 mg qd
  15-29 35 mg first dose, then 25 mg qd
  5-14 35 mg first dose, then 15 mg qd
  <5 35 mg first dose, then 10 mg qd
Adefovir
  ≥50 10 mg qd
  20-49 10 mg every other day
  10-19 10 mg every third day
  Hemodialysis patients 10 mg every week following dialysis
Entecavir NA naïve Lamivudine refractory/resistant
  ≥50 0.5 mg qd 1 mg qd
  20-49 0.25 mg qd or 0.5 mg q48 hr 0.5 mg qd or 1 mg q 48 hr
  10-19 0.15 mg qd or 0.5 mg q 72 hr 0.2 mg qd or 1 mg q 72 hr
  <10 or Hemodialysis* or CAPD 0.05 mg qd or 0.5mg q 7 days 0.1 mg qd or 1 mg q 7 days
Telbivudine
  ≥50 600 mg qd
  30-49 600 mg q 48 hr
  <30 (not requiring dialysis) 600 mg q 72 hr
  End-stage renal disease 600 mg q 96 hr*
Tenofovir
  ≥50 300 mg q 24 hr
  30-49 300 mg q 48 hr
  10-29 300 mg q 72-96 hr
  <10 with dialysis 300 mg q 7 days or after a total of approximately 12 hr of dialysis
  <10 without dialysis No recommendation
This table was adapted from AASLD guidelines (Hepatology 2009;50:661-662).
3
CAPD, continuous ambulatory peritoneal dialysis. 
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tory score by ≥2 points was reported in 49-56% of patients.
9-11 
The proportion of patients achieving HBeAg seroconversion 
increased substantially with continued LAM treatment to 50% 
after 5 years. The incidence of HBeAg seroconversion was 
greater in patients with higher baseline ALT concentrations.
12,13 
In HBeAg-negative chronic hepatitis B patients, undetectable 
serum HBV DNA at one year is observed in 60-70% of patients 
who received LAM.
14-16 In patients with bridging fibrosis or 
compensated cirrhosis, LAM can improve clinical outcomes.
17,18 
LAM significantly delayed overall disease progression and 
reduced the incidence and the risk of HCC compared to a pla-
cebo control group (7.8% vs 17.7%, and 3.9% vs 7.4%, respec-
tively).
18 LAM is also beneficial in patients with decompensated 
cirrhosis caused by actively replicating HBV. Significant clinical 
improvement, defined as a decrease in the Child-Pugh-Turcotte 
score by ≥2 points, was observed in 55% of patients.
19 However, 
it takes 3 to 6 months to show clinical benefit, and HCC can oc-
cur even among patients with clinical improvement. Studies from 
Asia reported lower rates of durability of improvement (50-60%) 
than those from non-Asian countries (77%).
20-22 Factors associ-
ated with increased durability of LAM-induced HBeAg serocon-
version were: longer duration of therapy after HBeAg serocon-
version, younger age, a lower HBV DNA level when treatment 
was stopped, and genotype B versus C. 
Mutations in the YMDD motif (rtM204V, rtM204I) are the 
primary mutants responsible for LAM resistance. The other mu-
tations such as rtL180M, rtL80I/V, and rtV173L are frequently 
found in LAM-resistant patients. The rtA181T/S and rtT184S 
mutations are rarely found. A study of 67 LAM-resistant Korean 
patients showed that the rtL180M, rtL80I and rtV173L mutations 
were present in 78%, 43%, and 11% of patients, respectively.
23 
The rtM204V mutation accompanied rtL180M, and rtL80I was 
always observed in conjunction with rtM204I. Genotypic resis-
tance was detected in 14-32% after 1 year of LAM treatment, 
and the frequency increased with each year of therapy, reaching 
60-70% after 5 years of treatment.
9-12,24 Factors associated with 
increase in the rate of LAM resistance include longer duration 
of treatment, higher pretreatment serum HBV DNA levels, and 
higher level of residual virus after initiation of treatment.
24,25 
2. Adefovir
Adefovir dipivoxil (ADV) is an orally bioavailable pro-drug 
of adefovir, a nucleotide analog of adenosine monophosphate. 
It can inhibit both reverse transcriptase and DNA polymerase 
activity and is incorporated into HBV DNA causing chain termi-
nation. The recommended dose of ADV for adults with normal 
renal function (creatinine clearance >50 mL/mim) is 10 mg 
orally daily. The dosing interval should be increased in patients 
with renal insufficiency (Table 3). 
In HBeAg-positive chronic hepatitis B patients, the HBeAg 
seroconversion rates at 1 year were 12% and 14% for patients 
who received ADV 10 mg and 30 mg compared with 6% for the 
placebo group. Mean reduction of serum HBV DNA level was 3.5 
and 4.8 log10copies/mL, and ALT normalization was observed 
in 48% and 55% of patients who received 10 mg and 30 mg 
ADV for 48 weeks, respectively. Histologic improvement was 
observed in 53% and 59% of patients who received 10 mg and 
30 mg ADV. But 8% of patients in the ADV 30 mg dose group 
had nephrotoxicity.
26 Cumulative HBeAg seroconversion was 
estimated to be 48% after 5 years of treatment.
27 In HBeAg-neg-
ative chronic hepatitis B patients, undetectable serum HBV DNA 
at 1 year was observed in 51% of patients who received ADV 10 
mg, and this increased to 71% after 2 years.
28,29 Another study 
has reported that serum HBV DNA was undetectable in 53% 
after 5 years of continuous ADV treatment.
30 ALT normaliza-
tion was observed in 72% of patients, and histologic response 
was observed in 64% of patients at 1 year of ADV treatment.
29 
Comparable results were observed at 1 year of ADV treatment 
in Asian chronic hepatitis B patients. Undetectable serum HBV 
DNA was observed in 39% of patients, and mean reduction of 
serum HBV DNA was 3.7 log10copies/mL. ALT normalization 
was observed in 63% and histologic improvement was observed 
in 56% of Asian patients.
31 
The rtA181T/V and rtN236T mutations are associated with 
ADV resistance. In vitro studies have shown that ADV-resistant 
mutations decrease susceptibility to treatment by 3 to 15 
folds.
32,33 A phase III trial showed no ADV-resistant mutations 
were found after 1 year of treatment,
34 but cumulative prob-
abilities of genotypic resistance to ADV at 1, 2, 3, 4, and 5 years 
were 0%, 3%, 11%, 18%, and 29%, respectively in HBeAg-
negative patients.
30 The cumulative rate of genotypic resistance 
to ADV was estimated to be 20% after 5 years of treatment in 
HBeAg-positive patients.
26 Risk factors for ADV resistance in-
clude suboptimal viral suppression and sequential ADV mono-
therapy in LAM-resistant patients.
35,36 In LAM-resistant patients, 
the cumulative genotypic resistance and virologic breakthrough 
at 5 years of sequential ADV monotherapy were reported to be 
65.6% and 61.8%, respectively.
37 
3. Entecavir
Entecavir (ETV) is a carbocyclic analogue of 2`-deoxyguano-
sine. It can inhibit HBV replication at three different steps: the 
priming of HBV DNA polymerase, the reverse transcription of 
the negative strand HBV DNA from the pregenomic RNA, and 
the synthesis of the positive strand HBV DNA. The approved 
dose of ETV for nucleoside-naïve patients is an oral dose of 0.5 
mg daily and 1.0 mg for LAM-refractory/resistant patients. The 
dose should be adjusted for patients with an estimated creati-
nine clearance <50 mL/min (Table 3). 
In HBeAg-positive patients, ETV resulted in significantly 
higher rates of virologic, histologic, and biochemical responses 
compared to LAM. In a Phase III clinical trial, serum HBV DNA 
was undetectable at 1 year in 67% of patients who received ETV 
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mg. Histologic improvement was observed in 72% and 62% of 
patients and ALT normalization was observed in 68% and 60% 
of patients, respectively. HBeAg seroconversion rates were also 
seen in 21% of patients who received ETV compared to 18% 
of patients who received LAM.
38 ETV resulted in earlier and 
more marked viral suppression than ADV.
39 In HBeAg-negative 
patients, ETV resulted in significantly higher rates of virologic, 
histologic and biochemical responses compared to LAM. More 
patients in the ETV group had undetectable serum HBV DNA 
levels (90% vs 72%) and normalization of ALT levels (78% vs 
71%) compared to that of the LAM group. Histologic improve-
ment after 48 weeks of treatment occurred in 70% as compared 
with 61% of patients in the LAM group. The mean reduction in 
serum HBV DNA levels from baseline to week 48 was greater 
with ETV than with LAM (5.0 vs 4.5 log10copies/mL).
40 In de-
compensated cirrhosis, a recent study showed that ETV resulted 
in virologic and biochemical responses similar to the compen-
sated liver disease group. Undetectable serum HBV DNA was 
observed in 89.1% of the decompensated group compared to 
78.5% of the compensated group. HBeAg seroconversion rate 
(48.1% vs 41.1%) and normalization of ALT (76.4% vs 75.0%) 
were also similar between the two groups.
41 
In HBeAg-positive patients who lost HBeAg and discontinued 
ETV therapy after 48 weeks, undetectable HBV DNA, normal-
ization of ALT and HBeAg seroconversion were sustained in 
39%, 79%, and 77%, respectively, at 24 weeks off-treatment.
42 
However in HBeAg-negative patients, only 3% sustained sup-
pression of serum HBV DNA to undetectable levels at 24 weeks 
after cessation of treatment.
43
Resistance to ETV appears to occur through a two-hit mecha-
nism with initial selection of the rtM204V/I mutation, followed 
by amino acid substitutions at rtT184, rtS202, or rtM250. In 
NUCs-naïve patients, the 5-year cumulative probability of ge-
notypic ETV resistance and genotypic ETV resistance associated 
with virologic breakthrough was only 1.2% and 0.8%, respec-
tively. In contrast, the 5-year cumulative probability of geno-
typic ETV resistance and genotypic ETV resistance associated 
with virologic breakthrough was 51% and 43%, respectively, 
in LAM-resistant patients.
44 In vitro studies showed that ETV-
resistant mutations are susceptible to ADV and TDF.
45 
4. Telbivudine
Telbivudine (LdT), a synthetic thymidine nucleoside analogue 
(L-enantiomer of thymidine), is phosphorylated intracellularly to 
the active triphosphate form, which competes with the natural 
substrate thymidine 5’-triphosphate to inhibit hepatitis B viral 
DNA polymerase; this enzyme inhibition blocks reverse tran-
scriptase activity, thereby reducing viral DNA replication. The 
approved dose of LdT is 600 mg daily. Doses should be adjusted 
for patients with estimated creatinine clearance <50 mL/min 
(Table 3).
In HBeAg-positive patients, LdT resulted in significantly 
higher rate of virologic and histologic responses compared to 
LAM. In a phase III clinical trial, undetectable serum HBV DNA 
at 1 year was observed in 60.0% of patients who received LdT 
600 mg compared to 40.4% of patients who received LAM 100 
mg. Histologic improvement was observed in 64.7% and 56.3% 
of patients, respectively. However, there was no significant dif-
ference in biochemical and serologic response rates. ALT nor-
malization was observed in 77.2% of patients who received LdT 
compared to 74.9% of patients who received LAM, and similar 
results were observed in HBeAg seroconversion rates, 22.5% 
for LdT group and 21.5% for LAM group.
46 After 2 years of 
treatment, LdT resulted in higher rate of sustained undetectable 
serum HBV DNA rates (55.6% vs 38.5%) and ALT normaliza-
tion (69.5% vs 61.7%) compared to LAM. The HBeAg serocon-
version rate was similar in two groups (29.6% vs 24.7%).
47 In 
HBeAg-negative patients, LdT showed a significantly higher 
rate of virologic response when compared to LAM. Undetect-
able serum HBV DNA levels at 1 year were observed in 88.3% 
of patients who received LdT, compared with 71.4% of patients 
treated with LAM. Results of histologic improvement and ALT 
normalization were similar in two groups: 66.6% vs 60.0% and 
74.4% vs 79.3% after 1 year of LdT and LAM treatment, respec-
tively.
46 After 2 years of treatment, LdT sustained a higher rate 
of undetectable serum HBV DNA (82.0% vs 56.7%) and similar 
ALT normalization rate (77.8% vs 70.1%) compared to LAM.
47 
Non-detectable serum HBV DNA at treatment week 24 was the 
strongest predictor for better outcomes for both HBeAg-positive 
and HBeAg-negative patients.
48 In Korean patients, similar an-
tiviral effectiveness of LdT was observed in a subgroup analysis 
of GLOBE phase III clinical trial.
49 
LdT selects for mutations in the YMDD motif. The rtM204I 
signature mutation was the primary basis for LdT resistance, 
with secondary mutations detected at the rtL80, rtL180, and 
other codons. The rtA181T mutation was detected in several LdT 
recipients but was not associated with viral breakthrough and it 
was replaced by wild type with continued LdT treatment in most 
patients.
47 In the phase III clinical trial, genotypic resistance af-
ter 1 and 2 years of treatment was observed in 5.0% and 25.1% 
of HBeAg-positive and in 2.3% and 10.8% of HBeAg-negative 
patients who received LdT, compared to 11.0% and 39.5% of 
HBeAg-positive and 10.7% and 25.9% of HBeAg-negative pa-
tients who received LAM, respectively.
46,47 In vitro studies have 
shown that HBV with the rtM204I mutation remains sensitive 
to the nucleotide analogues, ADV and TDF.
50 This is supported 
by the fact that switch or add-on ADV treatment reduced serum 
HBV DNA levels by 3.7 to 4.3 logs in 16 weeks, indicating that 
viral suppression can be restored by switch-to or add-on ADV.
47 
5. Tenofovir
Tenofovir disoproxil fumarate (TDF), an oral prodrug of teno-
fovir, is a nucleotide analogue with potent activity against HBV 
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studies have shown that TDF and ADV are equipotent. Since 
TDF appears to be less nephrotoxic, the approved dose is much 
higher than ADV; 300 mg vs 10 mg daily. The dose should be 
adjusted for patients with estimated creatinine clearance <50 
mL/min (Table 3). 
In HBeAg-positive patients, TDF 300 mg resulted in signifi-
cantly higher rate of undetectable serum HBV DNA (76% vs 
13%), ALT normalization (68% vs 54%), and HBsAg loss (3% vs 
0%) compare to ADV 10 mg at 1 year. TDF showed similar rate 
of histologic response (74% vs 68%) and HBeAg seroconver-
sion (21% vs 18%) compared to ADV.
51 After 3 years of TDF 
treatment, including some patients who received 1-year ADV 
treatment followed by 2-year TDF treatment, 72% of HBeAg-
positive patients had undetectable serum HBV DNA levels. ALT 
normalization was seen in 81%, HBeAg loss occurred in 34% 
and HBeAg seroconversion was observed in 26% of patients. 
HBsAg loss over 3 years was 8%.
52 In HBeAg-negative patients, 
TDF resulted in higher rate of undetectable serum HBV DNA 
than ADV (93% vs 63%). Histologic improvement and ALT nor-
malization were similarly observed in two groups (72% vs 69% 
and 76% vs 77%, respectively).
51 After 3 years of TDF treatment, 
including some patients who received 1 year of ADV treatment 
followed by 2 years of TDF treatment, 87% of HBeAg-negative 
patients had undetectable serum HBV DNA levels. ALT normal-
ization was observed in 74% of patients. No patient achieved 
HBsAg loss up to 3 years.
52 In patients with decompensated 
liver disease, a phase II study showed tolerability failure was 
as infrequent as 6.7% in the TDF group, 4.4% in the TDF plus 
emtricitabine group, compared to 9.1% in ETV group (p=0.622). 
At week 48, serum HBV DNA <400 copies/mL was observed in 
70.5% of the TDF group, 87.8% of the TDF plus emtricitabine 
group, and 72.7% of the ETV group. ALT normalization was ob-
served in 57%, 76%, and 55% of patients and HBeAg serocon-
version occurred in 21%, 13%, and 0% of patients, respectively. 
Child-Turcotte-Pugh and Modification for End-stage Liver 
Disease scores improved in all groups.
53 TDF monotherapy was 
found to induce potent and long lasting antiviral response in 
NUCs-experienced patients with previous treatment failure (LAM, 
ADV, LAM plus ADV).
54
One study reported that alanine to threonine substitution at 
rtA194 was associated with resistance to TDF in patients with 
HBV and HIV co-infection.
55 A recent study has found that the 
rtA194T polymerase mutation is associated with partial TDF 
drug resistance and negatively impacts the replication com-
petence of HBV constructs. However, viral replication can be 
restored to wild type levels if these polymerase mutations occur 
together with precore or basic core promoter substitutions, as 
found in HBeAg-negative hepatitis B.
56 A phase III clinical trial 
reported that none of the amino acid substitutions in HBV DNA 
polymerase/reverse transcriptase that developed through 3 years 
of treatment were associated with decreased phenotypic sensi-
tivity to TDF.
57
6. Clevudine
Clevudine [1-(2-deoxy-2-fluoro-b-Larabinofuranosyl) thy-
minine, L-FMAU] is a nucleoside analog with an unnatural β-L 
configuration and has shown potent effect against HBV and 
some activity against Epstein-Barr virus in vitro. Clevudine 
inhibits the DNA-dependent DNA activity of HBV polymerase, 
as well as reverse transcription and priming. Clevudine has no 
effect on mitochondrial DNA metabolism at concentrations 
ranging from 0.1 to 200 μM, as measured by lactic acid produc-
tion, mitochondrial DNA content and structural effects.
57-59 The 
approved dose of clevudine is 30 mg daily orally. 
In HBeAg-positive patients, 59.0% in the clevudine group had 
undetectable serum HBV DNA levels (less than 300 copies/mL) 
at week 24. The proportion of patients who achieved normaliza-
tion of ALT levels was 68.2% in the clevudine group and 17.5% 
in the placebo group. HBeAg loss and seroconversion occurred 
in 15.3% and 10.0% of patients in the clevudine group at week 
48. These rates were similar to those in the placebo group (12.0% 
and 12.0%, respectively).
60 Compared with LAM, clevudine 
demonstrated greater virologic, serologic, and biochemical re-
sponses. Median reduction in serum HBV DNA at week 48 was 
4.27-5.2 log10copies/mL compared to 3.17-4.2 log10copies/mL in 
the LAM group. Undetectable serum HBV DNA was observed in 
60-73% and 38-40% in the clevudine and LAM group, respec-
tively. HBeAg seroconversion occurred in 11-18% of patients in 
the clevudine group compared with 11-12% in the LAM group 
at week 48.
61,62 In HBeAg-negative patients, 92.1% in the clevu-
dine group had undetectable serum HBV DNA levels at week 
24. The proportion of patients who achieved ALT normalization 
was 74.6% and 33.3% in clevudine and placebo groups at week 
24, respectively.
63 
However, in contrast to published data on the safety profile 
of clevudine based on short-term clinical trials, several studies 
reported relatively frequent chances of developing myopathy in 
patients who received longer therapy with clevudine. A recent 
study reported the emergence of myopathy in 32 patients (8.8%) 
out of 363 chronic hepatitis B patients receiving clevudine 
therapy for more than 6 months.
64 Myopathy associated with 
clevudine is characterized by a weakness in proximal muscles 
of the lower extremities with elevated muscle enzymes, presum-
ably caused by mitochondrial toxicities.
64
Virologic breakthrough occurred in 0-5.5% up to 1 year treat-
ment with clevudine.
60,63,65,66 In vitro phenotypic analysis showed 
that the mutation rtM204I was predominantly associated with 
clevudine resistance, whereas rtL229V was a compensatory 
mutation for the impaired replication of the rtM204I mutant. A 
study of 14 clevudine-resistant patients showed rtM204I in 85% 
of the patients, and rtA181V and rtA181T were each observed 
in 1 patient.
67 All of the clevudine-resistant clones were resistant 
to LAM .
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TREATMENT OF NAÏVE PATIENTS
Drugs with potent antiviral activity and a high genetic barrier 
(ETV or TDF) should be used for NUCs-naïve patients. The rate 
of partial response assessed at week 48 was 45% in HBeAg-pos-
itive naïve patients receiving ETV. However, 83% and 89% of 
HBeAg-positive patients achieved HBV DNA levels <300 copies/
mL at week 96 and 144, showing long-lasting antiviral effect of 
ETV.
68
LAM was widely prescribed for patients with chronic hepatitis 
B owing to its antiviral efficacy and safety profile. Nonetheless, 
since LAM induces high rate of resistance, it is not recommend-
ed as first-line therapy. Switching from LAM to ETV mono-
therapy may be considerable. A study about the efficacy of ETV 
monotherapy in LAM-pretreated patients showed that HBV 
DNA suppression (<2.6 log10copies/mL) was achieved in 100% 
and 92% of patients after 2 years of ETV switching therapy ac-
cording to baseline HBV DNA levels (less than 2.6 and 2.6-5.0 
log10copies/mL, respectively).
69 Thus, switching to ETV should be 
considered in LAM-pretreated patients. Switching to TDF may 
have similar effects in this setting of patients.
A favorable long- term response was found in some patients 
receiving LAM or LdT. A 5-year follow-up study showed that 
90% of patients with two baseline factors (HBV DNA levels <9 
log10copies/mL, ALT ≥2xULN) and with week 24 HBV DNA of 
<3 log10copies/mL achieved HBeAg seroconversion, and 10% 
of them had YMDD mutations.
70 The GLOBE trial showed that 
HBeAg-positive patients with baseline HBV DNA of <9 log-
10copies/mL, ALT ≥2xULN and non-detectable HBV DNA at 24 
weeks of LdT therapy achieved HBeAg seroconversion in 52%, 
and LdT resistance in 1.8% at 2 years of therapy.
48 These results 
suggest that patients with non-detectable HBV DNA at 24 weeks 
of LAM or LdT therapy would have a good response to long 
term treatment with those drugs. 
TREATMENT OF DRUG RESISTANT PATIENTS
In the past, LAM was widely used for the treatment of chronic 
hepatitis B patients, and resistance to LAM developed in many 
patients. The development of LAM resistance limits future treat-
ment options. Sequential monotherapy with ADV or ETV for 
LAM resistance was associated with the frequent development 
of dual resistance to LAM and ADV or ETV. To avoid develop-
ment of multi-drug resistance, add-on therapy has been recom-
mended for anti-viral drug resistance. Drugs that are not cross-
resistant should be used for add-on therapy. It was reported that 
virologic breakthrough developed in 8 of 80 (10%) NUCs-naïve 
and 12 of 27 (44%) LAM-pretreated patients after 12 months of 
clevudine therapy.
67 Thus, clevudine therapy should not be con-
sidered for LAM pretreated patients. 
ADV add-on to ongoing LAM is the standard therapy for pa-
tients with LAM resistance. An Italian cohort study showed that 
none developed ADV resistance during a median of 40 months 
of treatment duration in patients with ADV added to LAM, 
whereas virologic breakthrough due to mutations developed in 
21% of patients receiving ADV monotherapy.
71 Add-on therapy 
was found to be more efficacious in patients receiving early 
treatment with ADV than in patients receiving treatment later at 
the time of high viremia levels.
72 
ADV monotherapy is still used in some patients with LAM re-
sistance because of the high cost of add-on therapy. In patients 
with LAM-resistant HBV, ADV monotherapy had been an estab-
lished treatment modality for several years, but recent studies 
have reported that it carries a significant risk for resistance in 
the long term.
71,73 Virologic and biochemical breakthrough with 
the emergence of ADV-resistant mutations occurred in 21% of 
patient who received ADV monotherapy at 15 to 18 months 
of treatment.
71 Another study has reported that ADV resistance 
reached 6% at week 192 in patients with HBV DNA <3 log10co-
pies/mL at week 48 of ADV monotherapy, compared with 49% 
at same time point in patients with HBV DNA >3 log10copies/
mL at week 48 of ADV monotherapy. These were HBeAg-nega-
tive patients with LAM resistance.
30 Thus, continuation of ADV 
monotherapy may maintain undetectable HBV DNA levels in 
patients with a complete response to ADV monotherapy. How-
ever, LAM should be added to ongoing ADV therapy in patients 
with only a partial virologic response to ADV monotherapy. 
Later addition of LAM to ADV monotherapy was found to ef-
fectively prevent the development of ADV resistance in patients 
with LAM resistance, comparable to the ADV addition to ongo-
ing LAM therapy.
74 LAM-resistant mutants remain susceptible to 
TDF, and TDF has a more effective anti-HBV effect than ADV. 
TDF add on therapy may be more effective in preventing the 
development of resistance than ADV add-on in LAM-resistant 
patients. 
Sequential ADV monotherapy for LAM resistance increases 
the development of multi-drug resistance to LAM and ADV, 
and resistance to LAM and ADV occurs even in LAM-resistant 
patients receiving combination therapy with LAM and ADV. 
ADV-resistant mutants remain sensitive to TDF or ETV. Sequen-
tial TDF monotherapy was report to completely suppress HBV 
DNA only in a minority of patients with dual drug resistance to 
LAM and ADV.
75 Recently, a prospective study showing efficacy 
of TDF rescue therapy for patients with failure of both LAM and 
ADV has been reported. Forty-six percent and 64% of patients 
with failure of both LAM and ADV (suboptimal response or ge-
notypic resistance) achieve an undetectable HBV DNA at 48 and 
96 weeks of TDF therapy, suggesting that TDF is the preferred 
drug in patients with prior failure or resistance to LAM and 
ADV. However, antiviral activity of TDF was found to be infe-
rior to that observed in naïve-patients and in previous studies.
76 
Combination therapy with ETV and TDF has been recommended 
for the treatment of patients with resistance to LAM and ADV.
50 
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suboptimal in these patients.
77,78 ETV monotherapy selected 
YMDD mutants in all patients within 48 weeks of therapy, re-
sulting in early development of ETV resistance.
77 The efficacy of 
combination therapy with LAM and ADV was compared with 
ETV monotherapy in these patients. Combination therapy with 
LAM and ADV was shown to be inferior to ETV monotherapy 
in suppressing HBV DNA.
79 However, drug resistance developed 
more frequently in patients receiving ETV monotherapy than 
patients receiving LAM plus ADV at 18 months of therapy.
80
ETV-resistant mutations are susceptible to TDF and ADV. TDF 
add-on therapy is recommended for ETV resistance by EASL 
and AASLD guidelines. ADV add-on therapy should be consid-
ered in ETV-resistant patients. However, the efficacy of ADV 
add-on therapy may be limited in ETV-resistant patients. 
CONCLUSIONS
The development of NUCs represents a significant advance 
in the treatment of chronic hepatitis B. Long-term treatment 
with NUCs has improved liver function and increased survival 
of patients. However, their major action is to suppress HBV rep-
lication, rather than eliminate HBV completely. The limitations 
are a higher chance of relapse after discontinuation of treatment 
and emergence of anti-viral resistance. Drugs with strong anti-
viral effect and a high genetic barrier to mutation, such as ETV 
and TDF, are recommended for the treatment of naïve-patients. 
The emergence of antiviral resistance limits treatment options. 
Add-on therapy with drugs without cross-resistance is a rule for 
drug resistance. Treatment options may be limited due to the 
unavailability and high cost of antiviral drugs. It is important 
that physicians make a judicious treatment plan based on indi-
vidual properties of each antiviral drug and the host’s immune 
status.
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